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Ebolaviruses cause a severe hemorrhagic fever syndrome that is rapidly fatal to humans and
nonhuman primates. Ebola protein interactions with host cellular proteins disrupt type I and type
II interferon responses, RNAi antiviral responses, antigen presentation, T-cell-dependent B cell
responses, humoral antibodies, and cell-mediated immunity. This multifaceted approach to
evasion and suppression of innate and adaptive immune responses in their target hosts leads to
the severe immune dysregulation and ‘‘cytokine storm’’ that is characteristic of fatal ebolavirus
infection. Here, we highlight some of the processes by which Ebola interacts with its mammalian
hosts to evade antiviral defenses.Introduction
The Filoviridae family consists of three genera: Marburgvirus,
Ebolavirus, and the newly identified Cuevavirus. Within the Ebo-
lavirus genus, there are five species, including Zaire ebolavirus,
Sudan ebolavirus, Bundibugyo ebolavirus, Taı¨ Forest ebolavirus,
and Reston ebolavirus. Filoviruses were first identified as the
causative agent of a hemorrhagic fever syndrome in Marburg,
Germany in 1967. Nine years later, the first two ebolaviruses
were described in the Democratic Republic of Congo (formerly
Zaire) and Sudan. Since then, more than 30 Ebola virus disease
outbreaks have infected thousands, with a mean case fatality
rate of65% in humans (Hartman et al., 2010). The recent Ebola
virus disease outbreak in West Africa began in March of 2014
and has thus far caused more than 8,000 confirmed and prob-
able cases, with a case fatality rate of about 50% (for the latest
information see: http://www.who.int/csr/disease/ebola/en/).
Virus Life Cycle
Ebola particles are enveloped, filamentous, and contain a mo-
nopartite negative-sense RNA genome. Though Ebola initially
targets macrophages and dendritic cells, it is able to infect
almost all cell types, with the exception of lymphocytes (Wool-
Lewis and Bates, 1998; Yang et al., 1998). Virus particles have
been proposed to attach to host cells through multiple plasma
membrane surface-expressed proteins (e.g., C-type lectins,
DC-SIGN, integrins, TIM-1, Axl) (Alvarez et al., 2002; Baribaud
et al., 2002; Kondratowicz et al., 2011; Lin et al., 2003; Schorn-
berg et al., 2009; Shimojima et al., 2006; Simmons et al., 2003;
Takada et al., 2000). Once attached to the plasma membrane,
the viral envelope glycoprotein induces particle uptake via mac-
ropinocytosis. The induction of macropinocytosis appears to be
dependent on the action of cell surface proteins, including TIM-1
and Axl (Aleksandrowicz et al., 2011; Brindley et al., 2011; Hunt
et al., 2011; Moller-Tank et al., 2013; Mulherkar et al., 2011;
Nanbo et al., 2010; Quinn et al., 2009; Saeed et al., 2010; Shimo-jima et al., 2007, 2006;Wen et al., 2013). After uptake intomacro-
pinosomes, particles travel to low-pH compartments of late
endosomes and lysosomes, where the viral envelope glycopro-
tein (GP) is proteolytically cleaved by endosomal cysteine prote-
ases (i.e., cathepsin B and L). This cleavage removes a heavily
glycosylated region from GP (Chandran et al., 2005; Dube
et al., 2009; Hood et al., 2010; Misasi et al., 2012; Schornberg
et al., 2006) and exposes a domain in GP that binds specifically
to the endosomal/lysosomal resident filovirus receptor Nie-
mann-Pick C1 protein (NPC1) (Carette et al., 2011; Coˆte´ et al.,
2011). Though current evidence suggests that NPC1 binding
may be sufficient to trigger fusion of the viral and cellular mem-
branes (Miller et al., 2012), it is as yet unclear whether additional
host proteins or intracellular conditions are necessary (e.g.,
reducing conditions, altered pH, additional protease cleavage)
(Brecher et al., 2012; Chandran et al., 2005) (Figure 1, left).
Once the viral and internal cell membranes fuse, the virus
particle uncoats and its anti-genome is transcribed into mRNA
using nucleocapsid-associated viral proteins. The virus genome
consists of seven viral genes—VP24, the nucleoprotein (NP),
VP30, VP35, the matrix protein (VP40), the RNA-dependent
RNA polymerase (L), and the glycoprotein—which are tran-
scribed into mRNA, resulting in the production of at least ten
proteins. Transcription of the genome is mediated via a complex
of VP30, VP35, and the viral polymerase L bound to an NP-
coated genome (Bharat et al., 2012; Hartlieb et al., 2003,
2007; Modrof et al., 2003; Mu¨hlberger et al., 1999; Sanchez
and Kiley, 1987; Sanchez et al., 1993). VP30 phosphorylation
leads to its dissociation from the VP35/L complex and is the
signal to switch from transcription to replication (Biedenkopf
et al., 2013; Martinez et al., 2011a). Following this switch, virus
genomes are replicated and coated by NP, VP24, VP30, and
VP35 (Mu¨hlberger et al., 1999). During assembly, L associates
with the ribonucleoprotein complex through an interaction with
VP35. The ribonucleoproteins then associate with the matrixCell 159, October 23, 2014 ª2014 Elsevier Inc. 477
Figure 1. Ebolavirus Life Cycle and Immune Avoidance Mechanisms
(Left) Virus particles attach to cell surface, inducing macropinocytosis and virus uptake, possibly using apoptotic mimicry to suppress inflammatory responses.
The particle is brought to a low pH compartment, where it is cleaved by cysteine proteases to reveal its NPC1 receptor-binding domain (RBD). Following fusion
and uncoating, the viral genome is transcribed into mRNA and viral proteins produced. Eventually, a signal to begin genome replication occurs, followed by
particle assembly and budding.
Expression and secretion of sGP serves as an antibody decoy for antibodies generated against GP. Viral proteins VP35, VP30, and VP24 are expressed and
mediate innate immune avoidance in all cell types. (Left) VP35 interferes with RIG-I/MDA-5 signaling and induction of interferon. Additionally, VP35 and VP30
block the RNAi response against viral gene expression. (Right) VP24 acts to inhibit type I and II interferon (IFN) signaling. This prevents interferon-induced gene
expression and, in antigen-presenting cells, blocks enhancement of antigen presentation to T cells.protein VP40, and viral particles are extruded through the
plasma membrane within lipid raft microdomain regions (Stahe-
lin, 2014) (Figure 1, left).
Sneaking in with the Trash: Apoptotic Mimicry
Ebolavirus particles can be up to a micron in length, making it
difficult for the viruses to enter via classic clathrin- or caveolin-
mediated endocytosis pathways, perhaps explaining the
requirement for macropinocytotic uptake. Interestingly, an
increased amount of phosphatidylserine (PS) may be present
on the surface of Ebola-virus-like particles (Jemielity et al.,
2013; Moller-Tank et al., 2013). PS is a lipid that is primarily pre-
sent on the inner leaflet of plasma membranes (Zachowski,
1993). Upon cell death via apoptosis, PS is exposed to the outer
leaflets of plasma membranes and apoptotic bodies. This alerts
nearby cells, including phagocytic cells, to begin ‘‘eating’’ the
debris via macropinocytosis in a process that is mediated by
TIM-1 and Axl and does not induce an inflammatory response
(Biermann et al., 2013; Morizono and Chen, 2014; Zago´rska
et al., 2014). This suggests the possibility that, similar to other
large viruses such as vaccinia virus (Mercer and Helenius,
2008), Ebola may induce macropinocytic uptake by appearing
to be an apoptotic body to phagocytic cells. This ‘‘apoptotic
mimicry’’ is anti-inflammatory and induces rapid uptake of a478 Cell 159, October 23, 2014 ª2014 Elsevier Inc.large virus into cells, thus avoiding humoral and cell surface im-
munity factors.
Snipping the Alarm Wire: Preventing the
Interferon Alarm
Evasion of host innate immune responses is of particular
importance to viruses, and many have evolved mechanisms to
circumvent innate immunity. Ebola inhibits both type I and type
II interferon responses in target cells, especially macrophages,
monocytes, and dendritic cells. The ultimate result is a defect
in dendritic cell maturation and diminished T-cell activation
and proliferation along with apoptosis leading to lymphopenia,
a key characteristic of Ebola virus disease. Studies in animal
models and in tissue culture suggest that both pathogenesis
and interferon antagonism are linked to VP35 and VP24 (Cilloniz
et al., 2011; Ebihara et al., 2006; Hartman et al., 2008a, 2008b;
Mateo et al., 2011; Prins et al., 2010; Reid et al., 2007).
VP35
VP35 is a viral polymerase cofactor that functions in RNA syn-
thesis and has been proposed to link L to NP. In addition to
these roles, VP35 plays a prominent role in Ebola’s inhibition of
a and b interferon induction through multiple mechanisms.
RIG-I and MDA-5 are innate pattern recognition receptors that
detect foreign cytosolic RNA. RIG-I recognizes 50-triphosphates
of blunt-ended RNA, and MDA-5 senses long double-stranded
RNA (dsRNA). Both signal via the downstream adaptor IPS-1
(a.k.a. MAVS, VISA, Cardif), resulting in NF-kB, IRF-3, and IRF-
7 activation with subsequent expression of type I interferon
and proinflammatory cytokines. Activation of IRF-3/7 is the result
of a signal cascade through which they are phosphorylated by
TANK-binding kinase 1 (TBK-1) and IkB kinase-ε (IKKε) (Chiang
et al., 2014). Early experiments determined that VP35 disrupted
the RIG-I pathway by preventing IRF-3 phosphorylation (Basler
et al., 2000, 2003). Later, VP35 was shown to interact with the
N-terminal kinase domain of IKKε in preventing IRF-3 phosphor-
ylation and acting as a decoy substrate for IKKε /TBK-1 kinases.
Furthermore, binding of VP35 to IKKε prevents interactions with
other proteins, including IRF-7 and IPS-1 (Prins et al., 2009). The
net result of these interactions is inhibition of the induction of
genes with interferon response promoters.
In addition to these downstream events in the RIG-I pathway,
VP35 interacts with dsRNA to prevent RIG-I and MDA-5 re-
sponses (Ca´rdenas et al., 2006). Structural and biochemical
studies revealed that VP35 contains a C-terminal interferon
inhibitory domain (IID) with two clusters of basic amino acids.
One cluster centers on residue R312 and participates in binding
to dsRNA. Further analysis revealed that VP35 binds to blunt-
ended dsRNA in a manner very similar to that seen with RIG-I
(Ca´rdenas et al., 2006; Leung et al., 2009, 2010a). Structural
studies of VP35 dsRNA binding are consistent with the finding
that VP35 prevents both RIG-I and MDA-5 responses. Observa-
tions from RNA-bound and -unbound structures revealed that
VP35 is able to bind both the phosphate backbone of dsRNA
and end-capped RNA in VP35 dimers. Mutations of the basic
patch centering on R312 abrogate dsRNA binding, and struc-
tural analysis suggests that R312 mutations disrupt VP35 dimer-
ization (Kimberlin et al., 2010). Experiments using recombinant
viruses incorporating mutant VP35R312A showed attenuation of
virulence and impairment of both virus growth and interferon
antagonism, suggesting that IID binding to dsRNA and VP35
dimerization play key roles in the virus life cycle and pathogen-
esis (Hartman et al., 2008a, 2008b; Kimberlin et al., 2010; Prins
et al., 2010).
Interestingly, comparisons of VP35 IID from the pathogenic
Zaire ebolavirus and Reston ebolavirus—thus far only patho-
genic in monkeys—revealed a slight decrease in interferon
antagonism and dsRNA binding by Reston. However, these de-
creases did not appear to contribute significantly to the differ-
ences in virulence between the Zaire and Reston viruses (Leung
et al., 2010b). Furthermore, comparison of the structures of the
Zaire and Reston VP35 did not reveal substantial differences
between the dsRNA recognition mechanisms (Kimberlin et al.,
2010). Together, these data suggest additional viral factors likely
play a role in the differential host responses between these two
viruses.
Recently, VP35 was found to interact with the PKR activator
(PACT) (Fabozzi et al., 2011). In addition to having activity in
RNA silencing and PKR activation, PACT binds to and activates
RIG-I. Subsequent work showed that VP35 binding to PACT pre-
vents PACT binding to RIG-I and inhibits RIG-I activation (Luthra
et al., 2013). VP35 binding to PACT ismediated by the same cen-
tral basic patch in IID that abrogates dsRNA binding describedabove, suggesting a possible role for dsRNA in this interaction.
Surprisingly, PACT interaction with VP35 inhibits the binding of
VP35 with L, causing a decreased efficiency of viral RNA synthe-
sis and genome replication, a phenotype of ‘‘mutual antago-
nism’’ (Luthra et al., 2013). Taken together with previous data,
these experiments point to the critical importance of VP35
antagonism of the RIG-I pathway during ebolavirus infection.
Additional VP35 interactions with cellular proteins have been
explored using a yeast two-hybrid system. These studies found
that VP35 interacts with IRF-7, Ubc9, and PIAS1 (Chang et al.,
2009). Ubc9 and PIAS1 are key components of the small ubiqui-
tin-related modifier (SUMO) system of posttranslational modifi-
cation, which regulates a variety of cellular pathways and
proteins. During SUMOylation, SUMO proteins are activated
by SUMO-specific proteases and are transferred to a SUMO-
conjugating E2 enzyme (e.g., Ubc9). Next, an E3 ligase, such
as PIAS1, is used to transfer the SUMO domain to a lysine on
the target protein (Wimmer et al., 2012). Studies with Ebola
VP35 found that it was able to block CpG-induced interferon in-
duction involving the IRF-3/7 pathway. Subsequent investigation
revealed that PIAS1 is able to SUMOylate IRF-7. VP35 expres-
sion enhanced SUMOylation of IRF-7, leading to suppression
of its activity and a decrease in interferon promoter activity.
Similar findings were noted with IRF-3 following expression of
VP35 (Chang et al., 2009). Thus, VP35-induced SUMOylation
of IRF-3 and IRF-7 leads to a further reduction in interferon a/b
gene transcription.
Arenaviruses (e.g., Lassa, LCMV) have taken a similar multi-
pronged approach to preventing type I interferon responses.
Lassa hemorrhagic fever has many characteristics similar to
Ebola virus disease, including the absence of interferon produc-
tion and lymphoid depletion. On the molecular level, arenavi-
ruses have been shown to suppress interferon production by
targeting both upstream (i.e., RIG-I/MDA-5) and downstream
signaling events (i.e., IKKε interactions, IRF-3 phosphorylation)
(Koma et al., 2013). In this way, each virus disrupts multiple
access points in the pathways that lead to increased interferon
production. Given the similarity in the clinical syndromes and
the common approach to interferon antagonism, further investi-
gations may provide insights into the underlying pathogenic
mechanisms of hemorrhagic fever syndromes.
VP24
When innate immunity is intact, the host response to virus infec-
tion causes secretion of interferon in order to generate antiviral
responses in neighboring cells, signal hematopoietic cell re-
sponses, and increase antigen presentation. Secreted interferon
binds to type I and II interferon receptors, inducing signaling via
adaptor proteins, and results in the phosphorylation and subse-
quent dimerization of signal transducer and activator of tran-
scription (STAT) proteins (e.g., STAT-1, STAT-2). Next, dimerized
phosphorylated STATs are transported to the nucleus where
they bind to interferon response elements and induce gene
expression (Ivashkiv and Donlin, 2014; Platanias, 2005). Given
the importance of these pathways for inducing antiviral gene
expression in response to interferon, they are commonly tar-
geted by viruses. For example, Dengue virus blocks STAT-1
phosphorylation and acts to degrade STAT-2 via proteasomal
degradation pathways (Green et al., 2014). Early experimentsCell 159, October 23, 2014 ª2014 Elsevier Inc. 479
with Ebola found that the virus not only blocked the production of
interferon, but also inhibited cellular responses that normally
result from both interferon a/b (type I) and interferon g (type II)
signaling. This signaling block was associated with the expres-
sion of the Ebola VP24 protein and later shown to prevent the nu-
clear accumulation of dimerized phosphorylated STAT-1 (Reid
et al., 2006), which participates in both type I (i.e., STAT-1/
STAT-2 phosphorylated-dimer) and type II (STAT-1/STAT-1
phosphorylated-dimer) signal propagation cascades (Ivashkiv
and Donlin, 2014; Platanias, 2005).
Phosphorylated STAT-1 dimer transport to the nucleus is
mediated by interactions with members of the nucleoprotein in-
teractor 1 family (i.e., karyopherin-a1, -a5, or -a6). Karyopherin-a
binds to nuclear localization signals (NLS) on cargo destined for
the nucleus. Downstream interactions with karyopherin-b and
other proteins allow the cargo to cross the nuclear membrane.
Unlike most nuclear proteins, dimerized phosphorylated STAT-
1 interacts with karyopherin-a through a unique noncanonical
NLS, allowing it preferential access to the nucleus. Biochemical
and structural studies have shown that VP24 binds to karyo-
pherin-a in the noncanonical NLS-binding domain. This blocks
phosphorylated STAT-1 dimer transport to the nucleus. Further-
more, VP24 binding to karyopherin-a does not appear to block
access to the canonical NLS-binding site (Mateo et al., 2010;
Reid et al., 2007; Xu et al., 2014). Therefore, the virus interfere
with both type I and type II interferon signaling without disrupting
routine trafficking to the nucleus of the infected cell.
Unphosphorylated STAT-1 is able to enter the nucleus using a
karyopherin-a-independent mechanism, where it is able to
induce and prolong the expression of interferon-induced im-
mune regulatory genes (Cheon and Stark, 2009; Meyer and Vin-
kemeier, 2004). Biochemical and structural studies with STAT-1
C-terminal truncation mutant demonstrated that VP24 binds effi-
ciently to STAT-1 lacking the tyrosine target for phosphorylation
(Zhang et al., 2012). This suggests an additional mechanism un-
related to phosphorylated STAT-1 dimer nuclear transport by
which VP24 is able to inhibit the induction of the interferon
response (i.e., by blocking the action of both forms of STAT-1).
In addition to the Jak-STAT pathway, type I interferon recep-
tors signal through the p38 MAP kinase pathway, where a signal
cascade of MAP kinases results in the phosphorylation of p38-a
(Ivashkiv and Donlin, 2014; Platanias, 2005). One study found
that VP24 was able to block the interferon-b-induced phosphor-
ylation of p38-a in HEK293T cells. However, this finding was cell
type specific, and the blocking mechanism has yet to be demon-
strated or generalized to cells that are primary targets of infection
(e.g., macrophages, dendritic cells) (Halfmann et al., 2011).
Like VP35, VP24 has been linked to Ebola pathogenesis. In
particular, experiments using mouse- and guinea-pig-adapted
variants of Ebola demonstrated that VP24, in conjunction with
other proteins such as NP, is critical to virus lethality (Cilloniz
et al., 2011; Ebihara et al., 2006; Mateo et al., 2011; Reid et al.,
2007). Structural analysis and comparison of Sudan and Reston
VP24 identified two conserved structural pockets that contain
residues implicated in the pathogenesis of VP24. Solvent ex-
change studies showed that this region may be near a proposed
STAT-1-binding region on VP24, suggesting that it may play a
role in STAT-1 binding and pathogenesis (Zhang et al., 2012).480 Cell 159, October 23, 2014 ª2014 Elsevier Inc.Taken together with previous studies on karyopherin-a, VP24
plays a role in pathogenesis through the disruption of both
type I and type II interferon signaling. Thus, Ebola not only dimin-
ishes the interferon alarm, but also inhibits the alarm response
after it has been heard. This coordinated approach between
VP35 and VP24 leads to a highly effective antagonism of the
innate immune responses mediated by interferons.
Silence Will Fall: Disrupting the RNAi Response
Infection of cells by RNA viruses activates an RNA-specific
inhibition (RNAi) pathway in host cells that silences viral gene
expression by cleaving viral RNA into small interfering RNAs
(siRNA) that bind and disrupt complementary RNA transcripts.
HIV-1 Tat is thought to suppress RNAi responses by blocking
Dicer activity, a key component of the RNA silencing complex.
Ebola VP35 suppresses cellular RNAi silencing and can comple-
ment HIV-1 Tat mutants. This suppression was lost when
mutations were made in the dsRNA-binding domains of VP35,
suggesting that VP35 may bind to siRNA or the dsRNA precur-
sors of siRNA (Haasnoot et al., 2007). Though subsequent
studies found that the C-terminal domain of VP35 bound to
siRNA and not to dsRNA, the RNAi silencing suppression activity
of VP35 did not correlate with binding to siRNA. It was hypothe-
sized that suppression via RNA-binding-independent mecha-
nisms could instead occur through binding to the RISC complex
or sequestration of RISC complex proteins prior to their incorpo-
ration into the complex (Zhu et al., 2012). This theory is sup-
ported by prior experiments which found that VP35 interacts
with transactivation response RNA-binding protein (TRBP) and
PACT (Fabozzi et al., 2011), both components of the RISC
RNAi complex and thus proposed to mediate the VP35-depen-
dent RNA-silencing suppressor activity. Interestingly, another
Ebola protein, VP30, also binds to components of the RISC com-
plex and acts as a suppressor of RNAi silencing (Fabozzi et al.,
2011). Similar to Ebola’s tactics for interferon antagonism, the vi-
rus uses two different viral proteins to disrupt the mammalian
RNAi innate immune response.
Plundering the Factories: Coopting Host Cellular
Functions
Protein Translation
Host cells thwart viral infection by decreasing cellular protein
synthesis in an effort to prevent or slow viral replication. This is
accomplished through the double-stranded RNA-dependent
protein kinase, PKR. Upon binding of dsRNA and activation,
PKR phosphorylates the a subunit of the eukaryotic translation
initiation factor-2 (eIF-2a). Ebola VP35 expression has been
shown to block PKR activity and enhance expression of proteins
after cells were treated with type I interferons. VP35 blocks PKR
by impairing phosphorylation of both PKR and the eIF-2a. Cur-
rent data suggest that this effect is mediated by the VP35 IID
domain; however, further work to elucidate the molecular mech-
anism is required (Feng et al., 2007; Schu¨mann et al., 2009).
RNA Stability and Replication
The heterogeneous nuclear protein complex C1/C2 proteins
(hnRNP C1/C2) are typically found in the nucleus where they
bind poly-U regions (>4) in mRNA and assist splicing prior to
mRNA export to the cytoplasm. They have also been shown to
participate in cap-independent, IRES-dependent translation in
the cytoplasm during mitosis (Shabman et al., 2011). Several vi-
ruses, including Dengue and poliovirus, have been found to co-
opt this function as a means to enhance viral protein synthesis
and replication (Brunner et al., 2005, 2010; Noisakran et al.,
2008; Pettit Kneller et al., 2009). Likewise, Ebola VP24 expression
causes the relocalization of hnRNPC1/C2 from the nucleus to the
cytoplasm. Interestingly, hnRNP C1/C2 also binds to karyo-
pherin-a via the same noncanonical NLS sequence STAT-1 and
VP24 use, suggesting a possible mechanism for redistribution.
It was hypothesized that, because the Ebola genomic and
mRNA sequences contain many poly-U tracts, hnRNP C1/C2
may interact with Ebola RNA to stabilize viral mRNA and enhance
genome replication (Shabmanet al., 2011). Thus, throughPKR in-
hibition and hnRNP C1/C2 relocalization, ebolaviruses co-opt
cellular machinery to optimize translation of gene products and
potentially prolong the half-life of viral messenger and genomic
RNA.
Escape from Alcatraz: The Tetherin Release Program
Tetherin is a type I interferon-inducible cellular factor that has
been shown to prevent enveloped virus budding from plasma
membranes. Tetherin contains two membrane-anchored do-
mains and is thought to mediate inhibition of budding by
anchoring between the cellular and viral membranes (Neil
et al., 2008). Tetherin was first described to antagonize retro-
virus and HIV-1 particle budding. These studies found that par-
ticle budding was rescued by the expression of HIV-1 Vpu (Neil
et al., 2008). When Ebola virus-like particles (VLP) were made
with VP40 in the presence of overexpressed tetherin, a similar
decrease in VLP release was noted and simultaneous expres-
sion of HIV-1 Vpu rescued particle release. VLPs with or
without GP expression showed that GP antagonized tetherin
activity and coimmunoprecipitated tetherin (Kaletsky et al.,
2009). Recent experiments suggest that residues within the
transmembrane domain of GP contribute to GP-dependent
tetherin antagonism (Gnirß et al., 2014; Ku¨hl et al., 2011).
Mechanisms proposed for GP-tetherin antagonism include
interference with tetherin integrity, steric hindrance by GP
that interferes with the formation of the tetherin connection be-
tween the viral and cellular membranes, and GP-dependent
exclusion of tetherin from the region of the plasma membrane
from which Ebola virus particles bud (Kaletsky et al., 2009). In
HIV-1, Vpu mediates cell-surface downregulation, relocaliza-
tion, and degradation of tetherin (Lopez et al., 2012). However,
Ebola GP does not appear to downregulate or alter tetherin
localization (Lopez et al., 2010, 2012), suggesting a novel anti-
tetherin mechanism.
The Host Strikes Back: Blocking the Entrances and Exits
The trade-off between efficient viral replication and pathoge-
nicity is a delicate balance that, when mismatched, can lead to
host demise. Therefore, viruses have evolved to suppress
immune responses in a selective and regulated manner that
facilitates controlled virus replication and progeny transmission.
In this section, we highlight two interferon-inducible genes that,
to date, are not known to be directly countered during Ebola
infection and lead to decreased virus infectivity.Interferon-induced transmembrane proteins (IFITMs) are
broadly active interferon-responsive restriction factors that
were first described as inhibitors of influenza A and have been
shown to be active against many enveloped viruses, including
Ebola and its cousin Marburg virus (Huang et al., 2011). IFITMs
are found in multiple membrane surfaces along cellular uptake
pathways and have been proposed to act by blocking virus entry
(Huang et al., 2011; Perreira et al., 2013). Several antiviral mech-
anisms have been proposed, including cholesterol accumula-
tion, inhibition of back fusion of virus containing vesicles in multi-
vesicular bodies, changes to membrane fluid dynamics, or
alterations in membrane curvature (i.e., restricting the capacity
for fusion between the virus and cellular membranes) (Amini-Ba-
vil-Olyaee et al., 2013; Perreira et al., 2013). Recent experiments
with IFITM-3 and influenza A virus suggest that IFITM-3 acts by
blocking an as yet undefined step between virus-cell membrane
hemi-fusion and fusion pore formation (Desai et al., 2014). Thus,
IFITM-3 allows the virus and celluar membrane lipids to mix but
does not allow the formation of a complete fusion pore. This pre-
vents the ribonucleoprotein core of the virus from gaining access
to the cytoplasm and blocks infection. Future experiments will
need to be performed to determine whether this mechanism
is applicable to Ebola and how some enveloped viruses (i.e., are-
naviruses) are able to avoid restriction by IFITMs.
Another interferon-stimulated gene that blocks Ebola infection
is ISG-15, a broadly active antiviral gene product that, when con-
jugated to a target protein, causes alterations to target protein
activity, cellular location, and stability. It has been shown to
affect many viruses, including influenza A/B, hepatitis B, HIV-1,
herpes simplex type 1, LCMV, and Ebola (Harty et al., 2009). In
the case of Ebola, the antiviral activity of ISG-15 was linked to
a disruption in VP40-mediated budding using VLP assays. Ebola
budding is, in part, mediated by Nedd4 ubiquitination of VP40.
Two groups found that ISG-15 interacts with Nedd4 and pre-
vents the ubiquitination of VP40, leading to inefficient particle
budding (Liu and Harty, 2010). Thus, together with IFITMs and
tetherin, these observations suggest that interferon-stimulated
genes have potent antiviral activities targeted against ebolavirus
during both entry and egress.
The resistance of freshly isolated monocytes to Ebola illus-
trates one example in which these factors may be playing a
role during infection. Experiments with Ebola GP-pseudotyped
VLPs found that particles were able to bind, but not enter, freshly
isolated monocytes. However, once the monocytes underwent
differentiation, the previously bound VLPs were able to enter
the monocytes, a result recapitulated using replicating Ebola
viruses (Martinez et al., 2013). Detailed analysis found that,
as the monocytes matured, IFITMs were downregulated while
both cysteine protease cathepsin B and NPC1 expression
were upregulated. These findings demonstrate how IFITM
restriction factors might play a role in the relative resistance to
infection of interferon-activated cells and also confirm the impor-
tance of NPC1 for Ebola infection.
Balancing the Scales of the Immune Response
A paradox in Ebola virus disease is that both survival and mortal-
ity are linked to the generation of strong immune signaling
responses in the host. Survivors and asymptomatic patientsCell 159, October 23, 2014 ª2014 Elsevier Inc. 481
have increased numbers of T cells and an early cytotoxic T-cell-
mediated response (Baize et al., 1999; Sanchez et al., 2004;
Wauquier et al., 2010). Rapid uptake of Ebola by macrophages
and dendritic cells not only results in translocation to lymphoid
and peripheral tissues, but alsomay explain the deficit in nonsur-
vivors of inflammatory cytokine secretion needed early after
exposure for the control of infection. Experiments using
in-vitro-cultured monocyte-derived macrophages found that
Ebola infection inhibited the secretion of TNF-a, IL-6, and IL-
10, consistent with impairments observed in association with
fatal disease outcome (Mahanty et al., 2003). Furthermore,
dendritic cells exposed to either live or inactivated virus failed
to upregulate molecules needed for T-cell co-stimulation, result-
ing in an inhibition of CD4 T-cell proliferation. Studies using
blood samples obtained from infected human subjects found
that IL-6 and TNF-a responseswere higher in survivors than non-
survivors at early time points. At later time points, IL-6 remained
higher in survivors, but the difference from nonsurvivors was less
dramatic due to increases in the latter group. In contrast to IL-6,
TNF-a in nonsurvivors was much higher than survivors late after
disease onset. It is interesting to note that IL-10 may play a crit-
ical role in modulating these responses. Although IL-10 was
mildly elevated in survivors, likely as a feedback mechanism to
control the inflammatory response, the increase was short lived,
as would be expected once cytokine levels returned to normal.
However, IL-10 was 6- to 10-fold higher in fatal cases and re-
mained elevated until death. In addition, monocyte/macrophage
activation as measured by neopterin levels was 2- to 10-fold
higher and consistently elevated in fatal cases (Baize et al.,
2002; Leroy et al., 2000, 2001), suggesting unregulated immune
activation. Though more recent studies showed different pat-
terns for specific cytokines (Wauquier et al., 2010), there is a
general trend toward survivors having a short-lived, balanced
pro- and anti-inflammatory response and nonsurvivors having
a delayed and prolonged inflammatory response that leads to
‘‘cytokine storm.’’
Together, these observations suggest that subjects able to
overcome innate immune response blocking by VP24, VP30,
and VP35 are more likely to establish an early, balanced, and
beneficial secretion of proinflammatory/anti-inflammatory cyto-
kines. In contrast, when early host antiviral innate responses
are blocked, uncontrolled virus replication and lysis of hemato-
poietic cells leads to late and unbalanced cytokine release,
overall dysregulation of immune responses, and the develop-
ment of advanced Ebola virus disease.
Camouflage and Misdirection: Avoiding Adaptive
Immune Responses
A fatal irreversible consequence of hematopoietic cell destruc-
tion by Ebola is reduced antigen presentation. This outcome is
consistent with the observation of poor IgG responses in fatal
infection, whereas high levels of IgG are associated with survival
(Baize et al., 1999; Ksiazek et al., 1999). Compounding inhibition
of IgG production, Ebola has evolved multiple properties that
could circumvent antibody effectiveness. Large filamentous vi-
rions containing high-density, stable glycoprotein present a po-
tential obstacle for efficient inhibition by antibodies, and virus
filament folding may create ‘‘pockets’’ of glycoprotein that are482 Cell 159, October 23, 2014 ª2014 Elsevier Inc.inaccessible to antibody binding. Furthermore, heavy glycosyla-
tion in the mucin-like domain of GP may limit access to critical
epitopes required for efficient neutralization (Martinez et al.,
2011b). Antibody access is restricted further due to rapid virion
uptake via macropinocytosis and intracellular receptor binding.
Additionally, ebolavirus hides its critical receptor binding domain
beneath a glycan cap, with exposure and receptor binding
occurring only after cathepsin-mediated removal of the cap.
This protection of a critical functional domain is analogous to
HIV, in which CD4 engagement of gp120 is required to expose
the coreceptor-binding site (Harrison, 2008). Furthermore, the
use of an intracellular receptor is a novel immune evasion strat-
egy that may be important for other viruses (e.g., Lassa fever vi-
rus [Jae et al., 2014]).
In addition to membrane-anchored GP, the glycoprotein gene
of Ebola encodes sGP, a 364 aa protein that is identical to GP in
its 205 N-terminal residues but is secreted by infected cells and
is not present in virions. The default transcript of the glycoprotein
gene is surprisingly not the virion-associated GP trimer but
instead dimeric sGP; the balance of expression of these two pro-
teins is governedby polymerase stuttering at anRNA-editing site.
This has led to speculation that sGP functions to modulate or
misdirect host immune responses (Kindzelskii et al., 2000; Yang
et al., 1998). The best evidence for this hypothesis comes from
a recent paper showing in mice that sGP promotes immune
evasion by serving as an antibody decoy for GP or by presenting
alternative nonneutralizing antibody epitopes for the humoral im-
mune response (Mohan et al., 2012). Remarkably, evidence sug-
gests that about 80% of glycoprotein gene expression is sGP.
Thismaybedue, inpart, to selectivepressures seeking tobalance
toxicity due to cytopathic effects of GP with the requirement for
GP on virus particles and avoidance of host immune responses
directed against GP (Yang et al., 2000, Volchkova et al., 2011).
Taken together, these data suggest that Ebola expression of
sGPandGP isa tightly regulatedprocess inwhich immuneshield-
ing and virus particle production are balanced via RNA editing.
In addition to immune evasion achieved through virion and GP
structural characteristics, GP exhibits direct immunosuppres-
sive properties (Chepurnov et al., 1999). sGP interacts with
neutrophils and disrupts the linkage between Fc g RIIIB and
CR3 (Kindzelskii et al., 2000). Furthermore, the Ebola transmem-
brane glycoprotein, GP2, bears structural similarity to retroviral
glycoproteins possessing an immunosuppressive peptide motif
(Volchkov et al., 1992) that was found to inhibit lymphocyte acti-
vation and proliferation (Yaddanapudi et al., 2006). Of particular
interest was the observation that the analogous immunosup-
pressive peptide from Reston virus was inhibitory only in ma-
caque, but not human, peripheral blood cells, implicating this
motif in Ebola pathogenicity.
Studies measuring in vivo antigen-specific T-cell responses
are limited by the difficulty of obtaining and preserving viable
lymphocyte samples from Ebola-infected subjects and survi-
vors. Nonetheless, data suggest that, over the course of Ebola
virus disease, there is a dramatic decrease in the absolute
numbers of T cells due to bystander apoptosis. This impairs
both direct cell-mediated killing of virus-infected cells and the
T-cell-dependent antiviral antibody responses (Sanchez et al.,
2004). Indirect measures of T-cell function based on serum
cytokine levels and RNA expression in isolated lymphocytes
suggest, as with immunoglobulin levels, an association between
intact cell-mediated immunity and survival (Baize et al., 1999;
Ksiazek et al., 1999; Sanchez et al., 2004; Wauquier et al.,
2010). In macaques, CD8+ T cells are essential for vaccine-
induced immune protection (Stanley et al., 2014; Sullivan et al.,
2011). Humoral responses clearly play a beneficial role in con-
taining virus but are not required for protection against some
Ebola species (Hensley et al., 2010; Stanley et al., 2014; Sullivan
et al., 2011). Antibodies participate in effective virus clearance
but likely require the presence of intact host cell-mediated re-
sponses (Wong et al., 2012). One speculative interpretation of
both human and macaque data is that immunoglobulin and
innate immune responses participate in containing early viral
loads but that cell-mediated immunity is needed for efficient vi-
rus clearance. The interplay and necessity of broad immune
response mechanisms is also suggested by Ebola evolution of
strategies to counteract each of these host antiviral defenses.
Taken together, these data suggest a complex interplay between
pro- and anti-inflammatory factors, resulting in either a balanced
immune response and host survival or dysregulation and death.Summary
Fatal Ebola infection is marked by a catastrophic failure of innate
and adaptive immunity that is mediated by virus-encoded
proteins as well as properties associated with virus structure.
At the heart of Ebola-induced immune dysregulation is a multi-
pronged attack on host antiviral immunity. Early and coordinated
disruption of host innate responses by VP24, VP30, and VP35
leads to elevated levels of virus replication, a cascade of inap-
propriately timed cytokine release, and death of both antigen-
presenting and -responding immune cells (Figure 1). This results
in a poorly activated adaptive immune response that is further
compromised by the induction of lymphocyte apoptosis and
antibody decoy mechanisms. In incidental hosts, this multifac-
eted approach to subversion of the immune system results in
high mortality that would be expected to limit virus persistence
in the absence of a distinct reservoir species.
Since first being identified almost 40 years ago, the genome
of Ebola has shown remarkable stability, an unusual feature for
RNA viruses with an error-prone polymerase. This suggests that
Ebola ishighlyadapted in its reservoir host.One intriguinghypoth-
esis is that additional host restriction factors limit pathogenicity in
a natural reservoir species. These factors would play a role in the
balance between immunity and sustained viral replication, allow-
ing the virus to propagate and persist over time in the reservoir
species. Outside this reservoir, sustained large outbreaks such
as theone inWestAfricamay lead toebolavirusadaptationsbeing
observed longitudinally, resulting in altered pathogenicity as the
virus adapts to humans. Overall, the multifaceted approach of
Ebola to selectively regulate immune responses and its variable
pathogenicity in different host species makes this virus both
scientifically interesting and a challenging foe.
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